COMMUNIQUÉS West-GlobeNewswire

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
10/02/2026
New appointment strengthens executive leadership commensurate with launch of CARDAMYST™ (etripamil) nasal spray MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: [...]
Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™
10/02/2026
Kennewick, WA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ (PRnT ™ ) with its innovative RadioGel ® technology, today provided an [...]
Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
10/02/2026
Financing led by Investissement Qu é bec with continued support from long-standing investors Plans include the acceleration of clinical development of breakthrough GPCR targeting treatments for patients MONTREAL and [...]
Fangzhou’s MaaS Platform Recognized as Industry Leader at Guangdong Digital Economy Conference
10/02/2026
GUANGZHOU, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, received prominent industry recognition at [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
10/02/2026
Bagsværd, Denmark, 10 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Yatiri Bio Accurately Predicts AML Drug Response in Blinded Study Using Foghorn’s FHD-286
10/02/2026
SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- A demonstrated 100% concordance between biomarker-guided predictions from pre-treatment patient samples and clinical outcomes validates Yatiri Bio’s platform as a [...]
Nicox : Présentation des données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l’American Glaucoma Society (AGS)
10/02/2026
Communiqué de presse Nicox : Présentation des données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l’ American Glaucoma Society (AGS) 10 février 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA [...]
Philips proposes to re-appoint CEO Roy Jakobs
10/02/2026
February 10, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Roy Jakobs is proposed to be re-appointed as its President/Chief Executive [...]
Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026
10/02/2026
Press Release Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026 February 10, 2026 – release at 7:30 am Sophia Antipolis, France Nicox SA (Euronext Growth Paris: [...]
Santhera Appoints Stifel as Corporate Finance Advisor
10/02/2026
Pratteln, Switzerland, February 10, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announced the appointment of Stifel Nicolaus Europe Limited (“Stifel”) as corporate finance advisor with a focus on capital markets [...]
Philips delivers full year 2025 with growth acceleration, strong margin expansion and solid cash flow; announces 2026-2028 targets at Capital Markets Day
10/02/2026
Amsterdam, February 10, 2026 Full year and Q4 highlights Comparable order intake growth 6% in 2025; up 7% in Q4 Group sales of EUR 17.8 billion in 2025, EUR 5.1 billion in Q4; comparable sales growth 2% in 2025, 7% in [...]
Restore Brain Highlights New Insights on How TMS Therapy Works Following Dallas Behavioral Health Summit
10/02/2026
Restore Brain executive John Cavanagh shared neuroscience-based insights on TMS during a recent behavioral health summit held in Dallas Restore Brain Logo DALLAS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Restore Brain, a multi [...]
Fangzhou ’XingShi’ Large Language Model Highlighted Among China’s Most Anticipated Healthcare Models for 2026
10/02/2026
SHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Industry research platform VBData recently highlighted “XingShi” Large Language Model (“XS LLM”) from Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leader in AI [...]
Propr® Launches Propr Picks: Innovative Floss Picks to Elevate Daily Oral Care
10/02/2026
NEW YORK, NY, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Propr ®, the fluoride free oral care brand founded by acclaimed periodontist Dr. Jack Gruber , today announced the launch of Propr Picks , a thoughtfully engineered dental [...]
DLH Reports Fiscal 2026 First Quarter Results
09/02/2026
ATLANTA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital transformation and cybersecurity, systems engineering and integration, and science [...]
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
09/02/2026
ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the closing of its initial public offering of 10, [...]
LifeStance to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 25, 2026
09/02/2026
SCOTTSDALE, Ariz., Feb. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its fourth quarter and full year 2025 [...]
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
09/02/2026
BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it [...]
Agomab Announces Closing of Initial Public Offering
09/02/2026
ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology [...]

Pages